Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.
After divorcing Denali Therapeutics earlier this month, Takeda is now splitting up with Veritas In Silico, pulling back from a partnership that advanced novel small-molecule drugs targeting mRNA.
Johnson and Johnson kicked off first-quarter earnings season with a “modest” beat and an ambitious goal; Replimune failed again to gain approval for its advanced melanoma therapy, as analysts tout increased accountability brought by the FDA’s new policy of publicizing complete response letters; and Revolution Medicines’ pancreatic cancer candidate doubled survival in one of cancer’s most intractable foes.
Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.
The Internal Revenue Service rarely penalizes taxpayers who have high balances in foreign bank accounts and fail to file the proper forms, according to a new report.
The Senate Finance Committee ranking member introduced two bills cracking down on grantor retained annuity trusts and private placement life insurance.
The theme of this year’s survey is “Caught in the Middle,” exploring how caregiving responsibilities, as well as other responsibilities outside work, affect accounting professionals navigating their careers.
The Internal Revenue Service will need to be ready for a wave of tax return filings from procrastinating taxpayers, as well as requests for extensions.
From spotting anomalies to enhancing accuracy to streamlining client communication, tax preparers are no longer being bogged down by operational inefficiencies.